Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 11/20 | 0.43 |
| ▸ | SPR | P35270 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19096913 | 0.88 | HPGD (0.47) | EPHX2SPRKMT2AHTTCYP2C9 | |
| SCHEMBL19096862 | 0.88 | MEN1 (0.44) | LMNAEPHX2KMT2AHTTCYP2C9 | |
| SCHEMBL19096875 | 0.86 | MAPK1 (0.51) | KMT2ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL17328247 | 0.85 | EPHX2 (0.42) | LMNAEPHX2SPRCYP1A2CYP2C9 | |
| SCHEMBL19096873 | 0.83 | HPGD (0.50) | EPHX2KMT2A | |
| SCHEMBL19096884 | 0.81 | CNR1 (0.41) | LMNAKMT2A | |
| SCHEMBL19096916 | 0.81 | CPS1 (0.43) | LMNAKMT2AHTT | |
| SCHEMBL17318845 | 0.79 | SIGMAR1 (0.47) | EPHX2 | |
| SCHEMBL17318769 | 0.79 | SIGMAR1 (0.47) | EPHX2 | |
| SCHEMBL17318767 | 0.79 | SIGMAR1 (0.47) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10065971-B2 | Amide derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain | ESTEVE PHARMACEUTICALS S.A. (ES) | 2018-09-04 | — | — | US | disclosed |
| US-20170197984-A1 | AMIDE DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2017-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10065971-B2 | Amide derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain | OPRD1, SIGMAR1, OPRM1 | LMNA 4163/4885EPHX2 2094/4885SPR 3473/4885 |
| US-20170197984-A1 | AMIDE DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | OPRD1, SIGMAR1, OPRM1 | LMNA 4163/4885EPHX2 2094/4885SPR 3473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.